LV009 cell therapy for blood cancers, autoimmune diseases, and transplant antibody issues
This study tests a new cell-based treatment called LV009 in people with certain blood cancers, autoimmune diseases, or antibodies that make transplants difficult. The treatment is meant to fight the disease or reduce harmful antibodies, possibly helping patients who have not responded to other therapies.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be willing and able to give written informed consent.
- You must have a confirmed diagnosis of a relapsed/refractory blood cancer (like leukemia, lymphoma, or myeloma), an autoimmune disease (like lupus, multiple sclerosis, or myasthenia gravis), or antibodies that might block a future organ or gene therapy transplant.
- Your bone marrow, kidney, and liver function must be good enough for the trial.
- If you can have children, you must agree to use two forms of birth control during the study and for 90 days after the last dose.
- You must not have active brain metastases, hepatitis B/C, HIV, or an active infection with fever above 38°C within 3 days of starting.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental treatment called LV009 for people with certain types of blood cancers that have come back or not responded to previous treatments. The treatment targets a protein called CD19 found on cancer cells.
This trial tests a new treatment called LV009, a type of CAR-T cell therapy, for people with certain blood cancers (like leukemia or lymphoma) that have CD19 on their cells. The therapy uses your own immune cells to fight the cancer.
This study tests a new medicine called LV009 for people with certain blood cancers (like leukemia or lymphoma) that have come back or not responded to treatment. The goal is to see if LV009 is safe and works against these cancers.
This early-phase trial tests an investigational cell therapy called LVIVO-TaVec122 for people with certain blood cancers (lymphoma or leukemia) that have come back or not responded to previous treatments. The goal is to see if this new treatment is safe and works for you.
This trial tests a new cell therapy (FT839) designed to target and reset the immune system's B cells to help treat moderate to severe autoimmune diseases that haven't improved with standard treatments. It's an early-phase study, so the main goals are to see if it's safe and if it helps control the disease.
This trial tests a new cell therapy called YTS109 for people with certain severe autoimmune diseases that have not responded to standard treatments, such as lupus, Sjögren's syndrome, systemic sclerosis, inflammatory myopathy, vasculitis, and antiphospholipid syndrome. The goal is to see if it can safely reduce disease activity.
Hear when a new HLA/AAV Sensitization trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.